In our latest blog, we explore a powerful conversation that is gaining momentum across the cell and gene therapy landscape: breaking down data silos to accelerate access to life-saving therapies. In a recent video roundtable hosted by The Medicine Maker, leading industry figures challenge the prevailing culture of proprietary workflows. They examine how sharing operational and manufacturing data could dramatically speed up CAR-T production, improve efficiency, and reduce redundant effort.

Participants discuss a broad range of collaborative tools, from blockchain-backed shared data systems to cross-industry proof-of-concept initiatives, ultimately making one thing clear: collaboration is not a luxury, it is essential. By pooling data on process parameters, quality metrics, batch outcomes, and manufacturing challenges, institutions can uncover shared insights that would otherwise remain locked inside individual organisations.

The discussion delves into which kinds of data could realistically be shared across the industry, and crucially, why sharing matters. Access to anonymised, structured data would permit benchmarking, help to detect common failure modes, and drive continuous process improvement. Such radical collaboration not only has the potential to reduce time to manufacture and lower costs, but also to increase robustness, consistency and regulatory confidence.

Ultimately, by rethinking how we approach data ownership, the CGT industry can lay the foundations for a more open, scalable, and patients-focused ecosystem. The future of CGT manufacturing, as the roundtable makes clear, depends on our willingness to share, innovate, and build together.

Link to article